Coherus Oncology, Inc. (CHRS)

CHRS Revenue & Earnings

Coherus Oncology, Inc. (CHRS) reported revenue of $42.17M and net income of $-170,291,000 for FY 2025, with a net profit margin of -403.8%. Revenue represents total sales while net income is the profit remaining after all expenses. The relationship between them reflects overall profitability.